Tag : UNRESECTABLE OR METASTATIC HCC

In advanced HCC, the tumor microenvironment fosters immune evasion by upregulating inhibitory pathways that suppress cytotoxic T-cell activity. Nivolumab + ipilimumab enhance antitumor immune responses by blocking these inhibitory signals and restoring T-cell function. Nivolumab + ipilimumab has demonstrated superior overall survival (OS) and durable responses compared to sorafenib in untreated advanced HCC.3 Based on these findings, the dual immunotherapy has been approved by the FDA as a first-line treatment for patients with unresectable or metastatic HCC without prior systemic therapy, offering a promising alternative to kinase inhibitor-based therapies.